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[57] ABSTRACT 
Pharmaceutical compositions and methods of inhibiting 
the enzyme elastase and increasing the biological half 
life and/or potency in terms of inhibitory activity of the 
enzyme elastase of peptide compounds is achieved by 
use of a polymer of the formula P-(L—R)q wherein P 
is a polymer containing at least one unit of the formula 
(A,,B,,) wherein A,,B,, is substantially nonbiodegradable, 
and has an average molecular weight of about 1,000 to 
5,000 daltons, L is a covalent bond or a linker group and 
R is a peptide. . 
15 Claims, No Drawings 
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POLYMER BOUND ELASTASE INHIBITORS 
This application is a continuation of application Ser. 
No. 07/242,294 ?led Sep. 9, 1988 and now abandoned. 
TECHNICAL FIELD 
This invention relates to potent polymeric inhibitors 
of the enzyme elastase and to their utilization for inhibit 
ing the activity of the enzyme in animals and humans. 
The invention also relates to a method of increasing the 
biological half-life and/or the elastase enzyme inhibi 
tory activity of a peptide elastase inhibitor by binding 
multiple units of the inhibitor to a hydrophilic, ?exible 
and substantially non-biodegradable polymer. 
BACKGROUND ART 
Proteinases from polymorphonuclear leukocytes and 
macrophages, especially elastases ‘(human leukocyte 
elastase and cathepsin G), appear to be responsible for 
the chronic tissue destruction associated with in?amma~ 
tion, arthritis and emphysema. During infection or in 
?ammation, the normal lung is protected from proteo 
lytic digestion by the protease inhibitor, al-antitrypsin. 
The protective mechanism appears to be nonoperative 
in individuals with an al-antitrypsin de?ciency due to 
genetic or other causes. Synthetic elastase inhibitors 
5 
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capable of replacing ai-antitrypsin may therefore be ' 
useful in the treatment of pulmonary emphysema and 
related diseases. _ 
Several types of elastase inhibitors have been re 
ported in the literature. These include peptide chloro 
methyl ketones as described by P. M. Tuhy and J. C. 
Powers, “Inhibition of Human Leukocyte Elastase by 
Peptide Chloromethyl Ketones”, FEBS Letters, 50, 
359-61 (1975); J. C. Powers, B. F. Gupton, A. D. Har 
ley, N. Nishino and R. J. Whitley, “Specificity of Por 
cine Pancreatic Elastase, Human Leukocyte Elastase 
and Cathepsin G. Inhibition with Peptide Chloromethyl 
Ketones”, Biochem. Biophys. Acta. 485, 156-66 (1977); 
azapeptides, C. P. Dorn, M. Zimmerman, S. S. Yang, E. 
30 
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C. Yurewicz, B. M. Ashe, R. Frankshun and H. Jones, _ 
“Proteinase Inhibitors. 1. Inhibitors of Elastase”, J. 
med. Chem, 20, 1464-68 (1977); J. C. Powers and B. F. 
Gupton, “Reaction of Serine Proteases with Ala-amino 
Acid and Aza-peptide Derivatives”, Meth. Enzymol., 
46, 208-16 (1977); sulfonyl ?uorides, T. Yoshimura, L. 
N. Barker and J. C. Powers, “Speci?city and Reactivity 
of Human Leukocyte Elastase, Porcine Pancreatic Elas 
tase, Human Granulocyte Cathepsin G, and Bovine 
Pancreatic Elastase, Human Granulocyte Cathepsin G, 
and Bovine pancreatic Chymotrypsin with Arylsul 
fonyl Fluorides. Discovery of a new series of potent and 
speci?c irreversible Elastase Inhibitors”, J. Biol. Chem. 
257, 5077-84 (1982); heterocyclic acylating agents, M. 
Zimmerman, H. Morman, D. Mulvey, H. Jones, R. 
Frankshum and B. M. Ashe, “Inhibition of Elastase and 
Other Serine Proteases by Heterocyclic Acylating 
Agents”, J. Biol. Chem. 25, 9848-51 (1980); B. Ashe, R. 
L. Clark, H. Jones and M. Zimmerman, “Selective 
Inhibition of Human Leukocyte Elastase and Bovine 
ayChymotrypsin by Novel Heterocycles”, J. Biol. 
Chem. 256: 11603-60981); imidazole N-carboxamides, 
W. C. Groutas, R. C. Badger, T. D. Ocain, D. Felder, J. 
Frankson and M. Theodorakis, Biochem. Biophys. Res. 
Commun., 95, 1890 (1980); and p-nitrophenyl-N alkyl 
Carbamates, R. E. Sco?ed, R. P. Werner and F. Wold, 
"p-Nitrophenyl Carbamates as Active-Site-Speci?c 
45 
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Reagents for Serine Proteases”, Biochemistry, 16, 2492 
(1977). 
Some peptide Chloromethyl ketones have been 
shown to be effective in preventing elastase induced 
emphysema in animal models, A. Jaoff and R. Dearing, 
“Prevention of Elastase Induced Experimental Emphy 
sema by Oral Administration of Synthetic Elastase In 
hibitor”, Am. J. Respir. Dis. 121, 1025-3 (1980). How 
ever, there is considerable question whether such reac 
tive agents can be used for treating emphysema in hu 
mans. This is not surprising since the alkylating moieties 
in these inhibitors might render them toxic when used 
on a continuous basis. To be suitable for human use, an 
enzyme inhibitor has to show a high degree of selectiv 
ity and must have minimal toxic side effects. As a result, 
most drugs are molecules that reversibly bind to speci?c 
enzymes or receptor sites. Examples are the carbamate 
esters physostigmine and neostigmine which have been 
clinically used as inhibitors of acetyl choline esterases 
(A. G. Gilman, L. S. Goodman, and A. Gilman, “The 
pharmacological Basis of Therapeutics”, p. 101, Mac 
Millan Publishing Co. (1980)). 
US. Pat. No. 4,643,991, Tsuji K. et a], B.B.R.C. 
122(2):571 (1984) and Digenis, G. A. et al, J. Med. 
Chem. 29:1468 (1986) describe peptide elastase inhibi 
tors which are speci?c and active-site directed and are 
not subject to the disadvantages associated with other 
prior art compounds for this purpose. 
However, there is still a need for elastase enzyme 
inhibitors which are speci?c and active-site directed of 
increased biological half-life and elastase enzyme inhibi 
tory activity. 
DISCLOSURE OF THE INVENTION 
This invention relates to a polymer of the formula 
wherein 
P is a polymer comprising at least one unit of the 
formula (AmBn), wherein (A,,,B,,) is substantially non 
biodegradable and has an average molecular weight of 
about 1,000 to 500,000 daltons, m and n may be the same 
or different and are about 5 to 3,000, and A and B may 
be the same or different and at least one of A and B is 
capable of covalently binding to one of L and R; 
R is a compound selected from the group consisting 
of a compound C of the formula 
wherein X is oxygen or sulfur; 
R’ is selected from the group consisting of straight 
and secondary branch-chained (C1-C4) alkyl, (C2-C3) 
alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, and ben 
zyl, and 
R2 is selected from the group consisting of substituted 
and unsubstituted phenyl, wherein the substituents are 
selected from the group consisting of nitro, and penta 
?uoro, benzyl, CH2CF2CF2CF3, l-lower alkyl tetrazo 
lyl, l-phenyltetrazolyl, 2-thioxo-3-thiazolidinyl-, pyri 
dyl and benzothiazolyl, provided that when R2 is p 
nitrophenyl R’ is other than tert-butyl, benzyl or cyclo 
hexyl, and when X is sulfur R2 is other than benzyl; 
a compound D of the following general formula: 
5,162,307 
wherein 
X is O or S, 
R2 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —-CH2CF2CF2CF3, l-lower 
alkyltetrazolyl, l- phenyltetrazolyl, benzyl, 2-thioxo-3 
thiazolidinyl, pyridyl and benzothiazolyl, and 
R’ is selected from the group consisting of straight or 
secondary branch chained (C1-C4) alkyl, (C2-C3) alke4 
nyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, and benzyl, 
provided that when R2 is p-nitrophenyl R’ is other than 
tertiary-butyl, benzyl or cyclohexyl, and when X is 
sulfur R2 is other than benzyl; and 
a compound E of the formula 
wherein 
Z is -O-Suc-Ala-Ala; 
each said R being covalently bound to L or to one of 
A and B, 
L is selected from the group consisting of a covalent 
bond and a linker group which is covalently bound to R 
and one of A and B; and 
q is about 1 to m+n. 
This invention also relates to an elastase enzyme in 
hibiting composition, comprising 
an elastase inhibiting amount of the polymer de 
scribed above, and 
a carrier. 
Also part of this invention is a method of inhibiting 
the enzyme elastase in an animal or human in need of 
such treatment comprising administering to said animal 
or human an elastase-inhibiting amount of the polymer 
of this invention. 
This invention also relates to a method of inhibiting 
the enzyme elastase in an animal or human in need of 
such treatment comprising administering to said animal 
or human the elastase enzyme inhibiting composition of 
this invention described above. 
Also part of this invention is a method of increasing 
the biological half-life of a compound selected from the 
group consisting of a compound C of the formula 
wherein 
X is oxygen or sulfur; 
R’ is selected from the group consisting of straight 
and secondary branch- chained (C1-C4) alkyl, (C2-C3) 
alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, and ben 
zyl; and 
R2 is selected from the group consisting of substituted 
and unsubstituted phenyl, wherein the substituents are 
selected from the group consisting of nitro, and penta 
0 
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4 
fluoro, benzyl, CH2CF2CF2CF3, l-lower alkyl tetrazo 
lyl, l-phenyltetrazolyl, 2-thioxo-3-thiazolidinyl-, pyri 
dyl and benzothiazolyl, provided that when R2 is p 
nitrophenyl R’ is other than tert-butyl, benzyl or cyclo 
hexyl, and when X is sulfur R2 is other than benzyl; 
a compound D of the following general formula: 
wherein 
X is O or S, 
R2 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —CH2CF2CF2CF3, l-lower 
alkyltetrazolyl, l- phenyltetrazolyl, benzyl, 2-thioxo-3 
thiazolidinyl, pyridyl and benzothiazolyl, and 
R’ is selected from the group consisting of straight or 
secondary branch chained (C1-C4) alkyl, (C2-C3) alke 
nyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, and benzyl, 
provided that when RZis p- nitrophenyl R‘ is other than 
tertiary-butyl, benzyl or cyclohexyl, and when X is 
sulfur R2 is other than benzyl; and 
a compound E of the formula 
F F 
0 
ll 
Z-Pro-Clh-N-C-O F 
CH(CH3)2 
F F 
wherein 
Z is -O-Suc-Ala-Ala 
each said R being covalently bound to L or to one of 
A and B, 
L is selected from the group consisting of a covalent 
bond and a linker group which is covalently bound to R 
and one of A and B; and 
q is about 1 to m+n. 
In addition, this invention also relates to a method of 
increasing the elastase enzyme inhibitory activity of a 
compound selected from the group consisting of a com 
pound C of the formula 
wherein 
X is oxygen or sulfur, 
R2 is selected from the group consisting of phenyl, 
p-nitrophenyl, ' pentaflurophenyl, 
—O—CH2CF2CF2CF3, l-methyltetrazolyl, l-phenyl 
tetrazolyl, 2-thioxo3-thiazolidinyl, pyridyl, benzyl and 
benzothiazolyl, and 
R’ is selected from the group consisting of lower 
alkyl, lower alkenyl, lower alkynyl and benzyl, pro 
vided that when R is p- nitrophenyl R’ is other than 
tert-butyl, and when X is sulfur R is other than benzyl; 
a compound D of the following general formula: 
5,162,307 
wherein 
X is O or S, 
R2 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —CH2CF2CF2CF3, l-lower 
alkyltetrazolyl, 1- phenyltetrazolyl, benzyl, 2-thioxo-3 
thiazolidinyl, pyridyl and benzothiazolyl, and 
R’ is selected from the group consisting of straight or 
secondary branch chained (C1-C4) alkyl, (C2-C3) alke 
nyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, and benzyl, 
provided that when R2 is p- nitrophenyl R’ is other than 
tertiary-butyl, benzyl or cyclohexyl, and when X is 
sulfur R2 is other than benzyl; and 
a compound E of the formula 
0 
wherein 
Z is MeO-Suc-Ala-Ala; 
each said R being covalently bound to L or to one of 
A and B, 
L is selected from the group consisting of a covalent 
bond and a linker group which is covalently bound to R 
and one of A and B; and 
q is about 5 to m+n. 
A more complete appreciation of the invention and 
many of the attendant advantages thereof will be 
readily perceived as the same becomes better under 
stood by reference to the following detailed description 
when considered in connection with the accompanying 
?gures. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 depicts the inhibition of human leukocyte 
elastase (HLE) by various peptidyl carbamate deriva 
tives and m-proteinase inhibitor (alphay-PI) using 
MeO-Suc-Ala-Ala-Pro-VAL-NA as a substrate, where 
the concentration of the substrate is l.62>< 10"‘M and 
the concentration of the enzyme is 3.4><10—4M and 
FIG. 2 depicts the cumulative molecular weight dis 
tribution of the polymer-bound compound described in 
Example 2 (polymer IV). 
FIG. 3 depicts the absorption spectrum of the poly 
mer bound compound of Example 2 (polymer IV). 
FIG. 4 shows a gel permeation chromatography 
(GPC) analysis of the reaction mixture of the compound 
and the polymer of Example 2 (compound III) at vari 
ous times of the reaction. 
FIG. 5 depicts the binding of the elastase inhibitory 
peptide to the polymer (compound III) of Example 2. 
Other objects, advantages and features of the present 
invention will become apparent to those skilled in the 
art from the following discussion. 
BEST MODE FOR CARRYING OUT THE 
INVENTION 
This invention arose from a desire to improve on the 
biological half-life and/or potency of the elastase en 
25 
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zyme peptide inhibitors provided by the same inventors 
in US. Pat. No. 4,643,991. The inventors unexpectedly 
discovered that if multiple units of the known peptide 
inhibitors were covalently bound to a ?exible, linear 
polymer the product polymers had a surprisingly high 
biological half-life and/or potency with respect to the 
inhibition of the elastase enzyme. 
The polymers provided herein have the formula 
wherein 
P is a polymer comprising at least one unit of the 
formula (AmBn), wherein (AmBn) is substantially non 
biodegradable and has an average molecular weight of 
about 1,000 to 500,000 daltons, m and n may be the same 
or different and are about 5 to 3,000, and A and B may 
be the same or different and at least one of A and B is 
capable of covalently binding to one of L and R; 
R is a compound selected from the group consisting 
of a compound C of the formula 
wherein 
X is oxygen or sulfur; 
R’ is selected from the group consisting of straight 
and secondary branch-chained (C1-C4) alkyl, (C2-C3) 
alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl and ben 
zyl, and 
Rzis selected from the group consisting of substituted 
or unsubstituted phenyl, wherein the substituents are 
selected from the group consisting of nitro, pentafluoro, 
benzyl, CH2CF2CF2CF3, l-lower alkyl tetrazolyl, 1 
phenyltetrazolyl, 2-thioxo3-thiazolidinyl-, pyridyl and 
benzothiazolyl, provided that when R2 is p-nitrophenyl 
R’ is other than tert-butyl, benzyl or cyclohexyl, and 
when X is sulfur R2 is other than benzyl; 
a compound D of the following general formula 
wherein 
X is O or S, 
R2 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —CH2CF2CF;CF3, l-lower 
alkyltetrazolyl, l- phenyltetrazolyl, benzyl, 2-thioxo-3 
thiazolidinyl, pyridyl and benzothiazolyl, and 
R’ is selected from the group consisting of straight or 
secondary branch chained (C1-C4) alkyl, (C2-C3) alke 
nyl, (C2-C4) alkynyl, (C3-C5) cycloalkyl, and benzyl, 
provided that when R2 is p- nitrophenyl R’ is other than 
tertiary-butyl, benzyl or cyclohexyl, and when X is 
sulfur R2 is other than benzyl; and 
a compound E of the formula 
5,162,307 
7 
F F 
ll 
Z-Pro-CHy-N-C-O F 
CH(CH3)2 
F F 
wherein 
Z is MeO-Suc-Ala-Ala;' 
each said R being covalently bound to L or to one of 
A and B, 
L is selected from the group consisting of a covalent 
bond and a linker group which is covalently bound to R 
and one of A and B; and. 
q is about 1 to m+n. 
These polymers are suitable for the inhibition of the 
activity of the elastase enzyme both in vitro and in vivo. 
When they are utilized for inhibiting the elastase en 
zyme in vivo, solely pharmaceutically-acceptable poly 
mers are to be utilized. These are known in the art and . 
need not be speci?cally referred to herein. 
When the polymers of this invention are utilized in 
the in vitro inhibition of the enzyme they need not be 
pharmaceutically-acceptable. Accordingly, a signi? 
cantly larger number of polymers are ultimately suitable 
for the design of the inhibitory polymers of this inven 
tion for use in vitro. 
In general the polymers suitable for use in this inven 
tion are water soluble polymers, and preferably poly 
mers having a ?exible backbone structure which are not 
easily biodegradable and which consequently have a 
prolonged biological half life. Even more preferred are 
polymers which are water soluble and substantially 
non-biodegradable but which also have a ?exible poly 
mer backbone. A high ?exibility exhibited by the poly 
mer is helpful in increasing the accessibility of the poly 
mer bound inhibitory molecule to the enzyme. 
Suitable polymers for use in this invention are poly 
mers containing amide bonds in the main chain. Particu 
larly useful are derivatives of synthetic polyamino 
acids, examples of which include random copolymers of 
a, B hydroxy alkyl-D,L-aspartamide, e.g., poly a, B-[N 
(2-hydroxyethyl)-D,L-aspartamide] in which a fraction 
of Z-hydroxyethyl side-chains is replaced by said ap 
pended reactive moiety. 
Other examples of suitable polymers include polysac 
charide derivatives, especially derivatives of dextran, 
cellulose, carboxymethyl cellulose, alginic acid and 
hyaluronic acid or combinations thereof or combina 
tions with other polymers . Yet another example of 
suitable polymers with oxygen atoms in the main poly 
mer chain are polyether polymers, examples of which 
include polyethyleneglycol (polyoxirane), divinylether 
maleic acid copolymer (pyran copolymer, DIVEMA), 
and the like. 
Examples of polymers with a-C-C- backbone suitable 
for use in this invention are copolymers prepared from 
mixtures of different types of monomers. One such 
group is a polymer formed by mixing one type of mono 
mer which has reactive appended moieties and another 
type of monomer lacking such moieties. Particularly 
suitable are copolymers derived from hydrophilic vi 
nylic and/or acrylic type monomers, examples of which 
include N-Z-vinylpyrrolidone, Z-hydroxzypropylme 
thacrylamide, 2-hydroxyethyl methacrylate and' other 
hydrophilic esters and amides of arylic and methacrylic 
acid which are well known in the art. Suitable mono 
40 
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mers containing appended reactive moieties for prepa 
ration of copolymers for use in this invention include, 
e. g., maleic acid anhydride and reactive esters of acrylic 
and methacrylic acid. Particularly suitable are, e.g., 
glycidyl acrylate, glycidylmethacrylate, p-nitrophenyl, 
N-hydroxysuccinimide, pentachlorophenyl or/and pen 
ta?uorophenyl esters of methacrylic and acrylic acids, 
wherein the alkoxy moiety of the reactive ester can be 
either bound directly to the carbonyl of methacrylic or 
acrylic acid or it can be bound via a spacer linker. Suit 
able spacer linkers for use in these types of polymers are 
generally known in the art. Examples of particularly 
suitable polymers include poly(N-vinylpyrrolidone), 
copoly-(N-vinylpyrrolidone-co-maleic acid anhydride), 
copoly-(N-vinylpyrrolidone-co-methacryloyl-N 
Hydroxysuccinimide, copoly(N-(2-hydroxypropyl)me 
thacrylamide-co-methacryloyl p-Nitrophenyl ester) and 
other copolymers formed by the monomers indicated 
above. ' 
The linkers or spacers optionally incorporated in the 
polymer-bound inhibitors of the invention must contain 
at least two reactive groups. One of the reactive groups 
must be capable of covalently bonding to the appended 
moiety present in at least some of the monomer units 
contained in the polymer. The other reactive group 
must be capable of covalently bonding to a reactive 
group present in the free inhibitor molecule which is not 
involved in the binding to the active site of the enzyme. 
Suitable linkers are known in the art and need not be 
speci?cally described herein. One group of linkers 
which has been found suitable for use with this inven 
tion is that encompassing ?exible backbone hydrocar 
bons containing at least two reactive groups. Suitable 
are reactive groups such as hydroxyl, sulfhydryl, 
amino, carboxyl, hydrazino and hydrazido, among oth 
ers. However, other groups may also be utilized. The 
length of the linker or spacer may vary as desired for 
particular applications. Typically, (Cg-C20) hydrocar 
bori linkers are utilized, preferably linear hydrocarbons. 
However, other types of molecules may also be incor 
porated herein. 
‘A particularly suitable type of linker has been found 
to be those comprising (Cl-C20) hydrocarbons having 
covalently bonded substituents to the ?rst and last car 
bon atoms such as hydroxy amines. Other examples 
suitable for use in this invention are a, w-diamines, 0.,m 
diamino alcohols and a, m-diamino acids. 
The novel substituted carbamate compound poly 
mers, the pharmaceutical compositions containing them 
and the method for using these polymers are exempli 
?ed in the speci?c inhibition of porcine pancreatic elas 
tase and human leukocyte elastase without affecting the 
similar serine dependent proteases, bovine pancreatic 
trypsin and chymotrypsin. 
It is known from the art that proteases from polymor 
phonuclear leukocytes and macrophages, especially 
elastases (human leukocyte HL elastase and cathepsin 
G) appear to be responsible for chronic tissue destruc 
tion associated with inflammation, arthritis and emphy 
sema. During infection or in?ammation, the normal 
lung is protected from proteolytic digestion by the pro 
tease’ inhibitor, al-antitrypsin. This protective mecha 
nism appears to be non-operative in individuals with an 
al-antitrypsin de?ciency due to genetic or other causes. 
Synthetic elastase inhibitors capable of replacing a; 
antitrypsin are therefore useful in the treatment of pul 
monary emphysema and related diseases. 
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According to the present invention, a class of known 
compounds containing carbamate functionality and 
oligopeptides which are active-site directed inhibitors 
of elastase in animas and humans have been found to 
exhibit an increased biological half-life and/or potency 
when multiple units thereof are bound to a substantially 
non-biodegradable polymer. Polymers with multiple 
bound peptidyl carbamate chains therefore provide an 
opportunity to incorporate multiple inhibitory moieties 
into a single unit, thereby increasing the efficiency of 
the transfer of the acrylating moiety to the active site of 
the enzyme. This, in turn, optimizes the affinity of the 
polymer inhibitor towards the enzyme in comparison 
with the low-molecular weight inhibitory peptides 
themselves. 
The nature of the acylating moiety can be varied to 
optimize the duration of enzymatic inactivation as de 
sired. 
It is theorized that the mechanism of the invention 
takes advantage of the fact that carbamate esters react 
with proteases and esterases at the carbonyl carbon by 
losing the alkoxy portion thereof and transferring the 
carbamylating moiety to the active side of the enzyme. 
Deacylation then leads to the recovery of enzymatic 
activity. 
Suitable carbamate compounds which are active in 
accordance with the above proposals as elastase inhibi 
tors are various. These compounds are carbamates sub 
stituted by oligopeptides and may generally be de 
scribed by the following general formula C 
wherein 
Z is selected from the group consisting of R"O-Suc-, 
wherein R” is (C1-C3)alkyl, CF3CO— and/or a linker 
to a polymer. 
X is oxygen or sulfur; 
R’ is selected from the group consisting of straight 
and secondary branch-chained (C1-C4) alkyl, (C2-C3) 
alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl and ben 
zyl, and 
R2 is selected from the group consisting of substituted 
or unsubstituted phenyl, wherein the substituents are 
selected from the group consisting of nitro, pentafluoro, 
benzyl, CH2CF2CF2CF3, l-lower alkyl tetrazolyl, 1 
phenyltetrazolyl, 2-thioxo3-thiazolidinyl-, pyridyl and 
benzothiazolyl, provided that when R2 is p-nitrophenyl 
R’ is other than tert-butyl, benzyl or cyclohexyl, and 
when X is sulfur R2 is other than benzyl. 
In more preferred embodiments, the inhibitory pep 
tides may be described by the following general formu 
las D or E 
wherein 
R’ is (C1-C3) alkyl or a suitable linker to the polymer, 
X is oxygen or sulfur, and 
R2 is selected from the group consisting of phenyl, 
?uorophenyl, nitrophenyl, l-phenyltetrazolyl, l-lower 
alkyl tetrazolyl, benzyl, 3-thiazolidinyl, pyridyl and 
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benzothiazolyl, and R’ is straight or secondary branch 
chained (C2-C4) alkyl, (C2-C4) alkenyl, and (C2-C4) 
alkynyl, provided that when R2 is p-nitrophenyl R’ is 
other than tertiary-butyl, and when X is sulfur R2 is 
other than benzyl; and 
F F 
R‘ o 
I ll 
Z’—Pro—-CH2—N—C—O F 
F F 
wherein 
Z’ is selected from the group consisting of MeO-Suc 
Ala-Ala, CF3CO-Ala-Ala and a suitable linker connect 
ing this compound with a polymer; and 
R’ is as de?ned above but is preferably isopropyl. 
Suitable linkers are known in the art for the particular 
type of atom groupings present herein. 
In the inhibitory peptides suitable for use herein, the 
peptidyl carbamates are those wherein the amino por 
tion contains ‘the oligopeptide and the peptide portion is 
so chosen as to increase the speci?city of the carbamate 
ester for elastase. 
The peptides for the individual inhibitory compounds 
may be prepared by a sequential series of reactions 
beginning with L-proline protected on the ring nitrogen 
with ultimate coupling to the peptide. In the ?rst step, 
an N-protected proline, e.g., N-t-Boc-L-proline, is re 
acted with diazomethane to obtain the diazoketone 
followed by treatment with HCL to obtain the chloro 
methyl ketone protected L-proline. The chloromethyl 
ketone thus obtained is reacted with the appropriate 
amine HgNR' to form the protected amine derivative. 
The amine is in turn reached with the appropriate chlo 
roformate or thiochloroformate and deprotected by 
reaction with an acid such as HCl to provide the HCl 
salt. This compound is then coupled with Z-Ala-Ala by 
the mixed carbonic anhydride method to provide the 
compounds of the invention. The Z-Ala-Ala com 
pounds are obtained by reaction of Ala-Ala with methyl 
succinic acid N-hydroxy succinimide ester when 
Z=R”O—- Suc, e.g., MeOSuc. These Z-Aa»Ala inter 
mediates may be prepared according to the following 
scheme: 
HO-N 
o o // 
II II 0 
mo-ccmcmccx ——-———> 
o 
\\ 
Alam-Ala a II II mo-ccmcmc-o-n 
// 
0 
In conducting these reactions, the L-proline in the 
initial step is protected on the ring nitrogen by reaction 
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with any suitable protective agent known to the art so 
that reaction will occur on the carboxylic acid portion 
of the molecule. Preferably, the nitrogen atom in the 
ring is protected with a known protective agent, such as 
t-BOC. For example, t-BOC-Pro is available commer 
cially from Sigma Chemical'Company, St. Louis, M0. 
The protected proline is reacted with diazomethane by 
the method of Penke et al. (B. Penke, J. Czombos, L. 
Balaspiri, J. Peters and K. Kovacs, Helv. Chim. Acta., 
53:1057 (1970)). The resulting chloromethyl ketone is 
then reacted with the appropriate amine. This reaction 
is preferably conducted in a solvent solution, such as a 
lower alkyl alcohol, and preferably in the presence of an 
alkali metal iodide. The reactants are mixed under cool 
temperatures and then reacted at 50° to 75° C. to com 
plete the reaction. The evolved I-ICI is neutralized, as 
with a sodium carbonate solution, and extracted. This 
intermediate is then reacted with the appropriate chlo 
roformate or thiochloroformate and deprotected with 
hydrogen chloride to form the carbamate portion of the 
molecule. This molecule is then coupled with the pep 
tide portion of the molecule to form the ?nal product. 
This reaction procedure may be illustrated as follows: 
CHZNZ 
0 
ll 
t-Boc-UCOH % 
l? 
t-Boc-UCCHNZ % 
0 
, I‘ - NaI 
t-Boc-UCCPhCl ‘I? 
t-Boc-UCCl-QNHR’ yizg‘g 
i? if 
t-aoc—Ucciizil~z-c—xa 11% R. 
O 0 
II II _ _ 
HN CCHZNCXR MeOSuc Ala Ala ; 
I R, X = 8,0 
if 
MeOSuv-AIa-Ala-Pro-CI-h-lrl-C-XR 
R. 
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As pointed out above, the polymers of the invention 
may be employed as speci?c active site directed inhibi 
tors of the enzyme elastase. For this purpose the poly 
mers are preferably combined with a pharmaceutically 
acceptable carrier for the in vivo administration by 
injection or in the oral form. Conventional adjuvants 
and carriers may be employed in combination with 
about 1 to 90 wt % of the active polymer. The polymers 
may be administered to animals or humans at dosage 
amounts of about 0.1 mg/kg to 300 mg/kg, preferably 
about 1 mg/kg to 30 mg/kg, and still more preferably 
an average amount of about 12 mg/kg. 
The following examples illustrate preferred embodi 
ments of the invention but the invention is not consid 
ered to be limited thereto. In the examples and through 
out this speci?cation, parts are by weight unless other 
wise indicated. 
In synthesis of the compounds of the invention, melt 
ing points were determined on a Thomas-Hoover Uni 
Melt apparatus and are uncorrected. 'H NMR spectra 
were obtained using a Varian EM-36O (60 MH;) or 
EM-39O (90 MHz) spectrometer. Infrared (IR) spectra 
were recorded on a Perkin-Elmer 567 spectrophotome 
ter. Microanalyses were performed by Atlantic Mi 
crolab, Inc., Atlanta, Ga. or by Micro Analysis, Inc., 
Wilmington, Del. 
Reactions were routinely followed by thin layer 
chromatography (TLC) using Whatman MK6F silica 
gel plates. Spots were detected by UV Spectrophotom 
etry (254 nm), iodine or HBr-Ninhydrin spraying. Col 
umn chromatography was carried out using Silica Gel 
60 (Merck, Darmstadt, Germany). All compounds were 
identi?ed by spectral data and elemental analysis. 
The loading of the inhibitors onto the polymers either 
directly or by means of a linker spacer is conducted via 
chemical reactions which are known in the art and need 
not be described here in detail. The degree of loading, 
i.e., density of the PC units along the polymer chain, 
can be varied in such a way that it is the most appropri 
ate in accordance with the loading desired. This can be 
attained by varying the experimental conditions, e.g., 
the number of appended reactive moieties on the poly 
mer chain, the number of spacer groups and/or the ratio 
of PC to the polymer in the reaction. In the Examples ' 
appended hereafter speci?c reaction schemes are de 
scribed but are by no means intending to be limiting of 
the invention. 
Having now generally described this invention, the 
same will be better understood by reference to certain 
speci?c examples which are included herein for pur 
poses of illustration only and are not intended to be 
limiting of the invention or any embodiment thereof, 
unless so speci?ed. 
EXAMPLES 
EXAMPLE 1 
A peptidyl carbamate inhibitor (compound 5) suitable 
for the preparation of a polymer-bound inhibitor is 
prepared in accordance with the invention according to 
Scheme 1 hereinbelow. 
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OH QEEDQ 5 l)NaCH.A E _ _ _ 
l-Boc-—NH)\"/ 2) HCLAIa_OEt 2) cimc acid lBoc Ala Ala 
o 
o 
H 11/ 0 NO +113 Al Al ‘ OC— 3- a 
HCLN \H/ 2 
0 
(2) . 
1) iBuOCOCl 
2) TEA, ~15" c. 
3) 2 
O 
(3) 
HCOOH, HCl, EtOAc 
0° C. 
i? Y 
1 
HCLAla-Ala-N “Y0 
0 
N02 
(4) 
TEA, DMF 
0 
ll 
Co, 80° 0, 2% HO 
ll 
0 
o 
t? '1 T 0 
Al --Al —N \/ 
HO/\/\/ a a ll (5) 0 
O 
The individual steps of the procedure are described 5 
hereinbelow in greater detail. 
EXAMPLE 2 
Synthesis of t-Boc-L-alanyl-L-alanine (Compound 1) 
To a solution of t-Boc-L-alanine (5.9 g, 31.2 mmol) 60 
and L-alanine ethyl ester hydrochloride (4.8 g, 31.2 
mmol) in CHzClz/MCOH (4:1) is added triethyl amine 
(4.3 ml, 31.2 mmol) with stirring at room temperature. 
To this reaction mixture is added l-ethoxycarbonyl 
Z-ethoxy-l,2-dihydroquinoline (EEDQ) (8.0 g, 32.3 65 
mmol) and stirring is continued overnight. 
The mixture is then extracted into CH3C12(1O0 mml) 
and washed with 10% citric acid (50 ml><3) and 5% 
(1) 
N02 
NaHCO3 (50 ml). The organic layer is dried (Na2SO4) 
and concentrated in vacuo. 
The resulting oil is dissolved in EtOH (100 ml) and 30 
m1 of 1.0N KOH are added and the mixture stirred at 
35-40 C. overnight. The evaporation of EtOH is fol 
lowed by addition of citric acid (14 g in 50 ml H2)) to 
neutralize the excess KOH. 
The reaction mixture is then extracted into EtOAc/ 
tetrahydrofuran (THF) (150 ml><2 1f 1:1 mixture) and 
dried (Na2SO4). The solvent is then evaporated to give 
the product (1) which is purified by silica gel column 
chromatography (CH24Cl2/EtOAc 10:1) (121 g, 74%) 
mp. 89-91 C. in accordance with Doyle, B. B.; Traub, 
W.; Lorenz, G. P.; Brown, F. R.; Blout, E. R., J. Mo]. 
Bio1., 51:47 (1970). 
5,162,307 
15 
EXAMPLE 3 
Preparation of p-Nitrophenyl 
N-(t-Boc-L-alanyl-L-alanyl-L-prolylmethyl)-N-isopro 
16 
Anhydrous HCI is then bubbled through the reaction 
mixture and the reaction is followed by thin layer chro 
matography (TLC). The solvent is evaporated and the 
formic acid is turned into an azeotropic mixture by 
pyl carbamate (Compound 3) 5 addition of n-heptane. The resulting oil is used in the 
To a solution of compound 1 (1.0 g, 3.9 mmol) in next Step without further pun?canon‘ 
THF (30 ml) cooled to —30° C. is added N-methylmor- EXAMPLE 5 
pholine (0.46 mL, 4.2 mmol) and the mixture is stirred . . 
for 5 min. Isobutyl chloroformate (0.55 ml, 4.2 mmol) in . Symhesls of p'nmophenyl . 
THF (2 ml) is added and stirring is continued for 10 min 10 N'(Succmyl'L'alanyl'L'alanyl'L'prolylmethyn'N'lso' 
at _15 c_ propyl carbamate (Compound 5) 
To this reaction mixture is added a suspension of To a solution of compound 4 (1.5 g, 2.9 mmol) in 
compound 2 (1.3 g, 3.5 mmol) and Nemethyl morpho-. DMF (20 ml) are added Et3N (0.5 mL, 3.6 mmol) and 
line (0.46 ml, 4.2 mmol) in acetonitrile (40 m1) at —40 C. succinic anhydride (0.35 g, 3.6 mmol) and the mixture is 
Stirring is continued for 1 hr at room temperature. 15 stirred at 80 C for 1.5 hr. Diethyl ether (60 ml) is then 
The reaction mixture is then filtered and the ?ltrate added to the cooled mixture, the precipitated Et3N.HCl 
extracted with CHCI , washed with 10% citric acid is ?ltered and the ?ltrate evaporated to give a pale 
(3X 10 ml), dried (Na2SO4) and the solvent evaporated yellow solid. The product is then triturated with 2% 
to give an oil. HCI, ?ltered and recrystallized from tetrahydrofuran 
Saturation with ethyl acetate (EtOAc) gives the solid 2° (THF)/ether to give 1.6 g of compound 5 (PCI) (94%). 
which is purified by silica gel column chromatography The characteristics of compound 5 are as follows. 
(6% CH3OH/CH C12) to give compound 3 (90%). mp: 185-186 C., 
The characteristics of compound 3 are found to be IR (K Br) Vmax 3300 2700, 1780, 1750, 1651, 1560, 
mp:170—l72 C., 1200 cm—1, 
1R (K Br) Vmax 1730, 1650, 1520, 1345, 1190, 1155 25 NMR (DMSO d6) 8 8.3 (2H, d, J=9 Hz), 1.06—1.6 
cm-l; (26H, m). 
NMR (CDC13) 8 8.20 (2H, d, .1 =9 Hz), 7.20 (2H, d, The anal. calculated for C26H35N9O10 1 H1O is C, 
J=9 Hz), 4.1-4.5 (tH, m), 3.5-3.7 (3H, m), 2.0 (4H, m), 53.43; H, 6.17; N, 11.94 and what is found is C, 53.34; H, 
1.5 (9H, s), 1.7-1.6 (21H, m). 30 8.41; N, 11.93. 
EXAMPLE 4 EXAMPLE 6 
Synthesis of p-nitrophenyl Peptidyl carbamate hemisuccinate prepared accord 
N-(L-alanyl-L-alanyl-L-proplylmethyl-N-isopropyl ing to Example 1 (compound 5 of Scheme 1) is bound to 
carbamate hydrochloride (Compound 4) 35 the polymer carrier. The overall procedure is illustrated 
Formic acid (1.25 ml) is added to a stirring solution of m scheme 2 hercmbelow' 
a compound 3 (0.7 g, 1.02 mmol) in EtOAc (7 ml). 
Scheme 2: 
Synthesis of Polymer-bound PC Inhibitor of Examnle 2 
O O O 
// // // 
43.3.5 
II II 11 
O O O 
(1) 
CH3 
.....N~HTO+CHS 
0 cu, 
2. H2N/\/OH 
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EXAMPLE 7 
Synthesis of a Carrier Polymer 
Polysuccinimide (I) is prepared and fractioned ac 
cording to the method described by Vlasak, J., Rypa 
cek, F., Drobnik, J ., Saudek, V., J. Polymer Sci., Poly 
mer Symp., 66:59-64 (1979). 
10 g of polysuccinimide (I) (the fraction with 
Mw=32,000) is dissolved in 50 ml of N,N'-dimethylfor 
mamide (DMF) and 2.80 g (0.01 mol) of mono-N-Boc 
1,2-diaminethane benzoate, and 0.8 ml (0.01 mol) of 
triethylamine are added. 
The reaction mixture is left at room temperature for 4 
days and then 11.0 ml (0.18 mol) of 2-aminoethanol are 
added and the reaction is continued for another 24 
hours. 
The mixture is then neutralized with acetic acid, dia 
lyzed against water and the polymer isolated by freeze 
drying. 20 
Yield: 9.20 g PHEA(AE-BOC) (compound II of _ 
Scheme 2). 
PHEA(AE-BOC) (Compound II) (8.50 g) is dis 
solved in 30 ml of tri?uoroacetic acid. The solution is 
left for one hour at room temperature and then dialyzed 
against distilled water (V isking Dialysis Tubing, Serva). 
The dialyzed solution is then concentrated to a vol 
ume of 30 ml by the ultra?ltration on an Amicon YM 10 
membrane and diluted again with water up to 200 ml. 
The ultra?ltration is repeated in the same way 5 times. 
The polymer is isolated from the retentate by freeze 
drying. . 
Yield: 6.5 of PHEA(AE) (Compound III of Scheme 
2). 
EXAMPLE 8 
Binding of Peptidylcarbamate-Hemisuccinite to the 
Polymer with Aminoethyl Spacer-Chains (PHEA-AB) 
Peptidyl-carbamate-hemisuccinate (compound 5 of 
Scheme 1) (0.586 g, 0.001 mol) and N-ethyl-N'-(3-dime 
thylaminopropyl) carbodiimide-hydrochloride (0.23 g, 
0.0012 mol) are reacted in 4.0 ml of DMF for 45 minutes 
in an ice bath. Then the ice cold solution containing 2.20 
g of polymer III (0.0012 mol of ——NH;) and 0.167 ml 
(0.0012 mol) of triethylamine in 12 ml of DMF is added 
thereto and the reaction mixture is stirred at 0°-4° C. for 
24 hours. 
The polymer product is then dialyzed against a phos 
phate buffer pH 7.00 containing 0.15M NaCl. The dia 
lyzed polymer is further puri?ed by gel permeation 
chromatography (GPC) on a Sephadex G25 F column 
(50X 300 mm) in the same buffer and the collected poly 
mer fractions are desalted by repeated ultra?ltration 
and dilution on Amicon YM 10 membrane. The poly 
mer inhibitor is isolated by freeze-drying from water. 
Yield: 1.35 g PHEA(AE-PC) (Compound IV of 
Scheme 2). 
EXAMPLE 9 
Identi?cation and Characterization of the Carrier 
Polymer and the Polymer-Bound Inhibitor 
The molecular weight distribution analysis of all pol 
ymers is performed by size-exclusion chromatography 
(SEC) on a mixed-bed column (Sepharose CL-4B:Se 
phacryl S 200 SF : : Sephadex G-25 SF, 16:5:3;13X350 
mm). - 
25 
35 
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0.05M phosphate buffer pH 7.50 containing 0.15M 
NaCl is used as eluent. 
The column is calibrated with standard samples of 
PHEA (Rypacek, F., Saudek, V., Pytela, J ., Skarda, V., 
Drobnik, J., Makromol. Chem. Suppl. 9:129-135 
(1985)). 
The elution pro?les are monitored by means of an 
ISCO model 1840 Spectrophotometric detector. The 
values of molecular-weight averages, MW and Mn, and a 
cumulative molecular-weight distribution are calcu 
lated from the SEC data. These data are shown in FIG. 
2. 
The contents of aminoethyl side chains in polymers 
III and IV are determined spectrophotometrically after 
the reaction of aminoethyl groups with 2,3,5-trinitro 
benzene sulphonic acid in accordance with Brown, H. 
H., Clin. Chem., 14:967, (1968). The data are shown in 
Table 1 hereinbelow. 
TABLE 1 
Molecular Characteristics of the Polymer 
Bound Inhibitor 
Composition Molecular weight 
Polymer (%) averages 
Structure A B C M,‘ M,, 
111 91.2 8.8 0 31,600 21,000 
1V 91.2 4.2 4.6 38,000 24,000 
The rnolecular-weighl-equivalent per one PC unit: 4042. i.e., 0.247 umol PC/mg of 
the polymer-bound PC. 
The content of peptidyl carbamate units in the polym 
er-bound inhibitor is determined from the absorption 
spectrum of the polymer-inhibitor (polymer IV) assum 
ing the value of 9700 mol-l 1.cm for molar absorptivity 
of the above PC inhibitor at 276 nm (the data are shown 
in FIG. 3). 
The time course of the binding reaction between the 
free PC and polymer III is followed by GPC. Typically, 
10 ul samples of the reaction mixture are withdrawn at 
appropriate time intervals, diluted with phosphate 
buffer (e.g., PBS) and applied onto a Sephadex G-25 SF 
(11 X40 mm) column. The ratio between the polymer 
bo_und PC inhibitor and the unbound low-molecular 
weight PC inhibitor is determined from the areas under 
the respective peaks of the elution curve monitored as 
the optical density at 276 nm (the absorption maximum 
for the free PC). The results are shown in FIG. 4 and 5. 
EXAMPLE 10 
Poly-41,13 -(N-(2-hydroxyethyD-D,L—aspartamide) 
copolymer with 6-aminohexyl spacer-chains (PHEA 
AH) was prepared according to the overall procedure 
described in Example 2, but using mono-N-t-BOC-1,6 
diarninohexane hydrochloride in place of mono-N-t 
BOC-7,2-diaminoethane. 172 mg of PHEA(AH) (0.1 
mmol of —NH2 groups) is reacted with 58.6 mg (0.1 
mmol) of peptidylcarbamate hemisuccinate prepared in 
Example 1 (compound 5 of Scheme 1) and 23.0 mg (0.12 
mmol of N-ethyl-N'-(3-dimethylaminopropyl) carbodi 
imide (EDC) hydrochloride in presence of 0. 12 mmol of 
triethylamine in dimethylformiamide (2 m1) at tempera 
ture 0°-4° C. for 20 hours. The polymer product is 
dialised against water and further puri?ed by GPC on a 
Sephadex G-25F column (Pharmacia) and the polymer 
inhibitor is isolated by freeze-drying from water. ' 
Yield: 118 mg of PHEA (AH-PC). 68% of PC origi 
nally added to the reaction is bound to the polymer 
producing thus polymer-bound PC containing 6.2 mole 
% of PC side chains. 
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EXAMPLE 11 
The copolymer of N-2-vinylpyrrolidone and O 
methacryloyl-N-oxy-succinimide (p(VP-CO-MANSu)) 
containing 8 mole % methacryloyl-N-oxy-succinimide 
comonomer is prepared by the copolymerization of said 
comonomers in dioxane with azo-bis-iso-butyronitril as 
initiator. 1.46 g p(VP-CO-MANSu) copolymer (1 mmol 
of N-oxy-succinimide ester groups) is reacted with 0.51 
g of mono-t-BOC-l,6-diarninohexane hydrochloride 
(2.0 mmol) in presence of 2 mmol of triethylamine in 
DMF (10 ml) at temperature 50° C. for 48 hours. The 
polymer product is then dialysed against distiled water, 
the solution is then concentrated to a volume about 5 ml 
and 5 ml of tri?uoroacetic acid is added. The reaction 
mixture is left at ambient temperature for 4 hours then 
dialysed against distilled water and the polymer is fur 
ther puri?ed by GPC on a Sephadex G-25-F column. 
(Sephadex: Trademark of Pharmacia Uppsala, Swe 
den). The polymer poly (V P-CO-MA-AH), i.e. copoly 
mer of N-2-vinylpyrrolidone and N-(6-aminohexyl) 
methyacrylamide is isolated by freeze drying from 
aqueous solution. The mole content of aminohexyl 
spacer-chains is determined to be 8.9 mole % from all 
monomer units of the copolymer. 
149 mg of poly (V P-CO-MA-AH) (0.1 mmol of 
-—NH2 groups) is reacted with 58.6 mg (0.1 mmol) of 
peptidyl-carbamate hemisuccinate (compound 5 of 
Scheme 1) obtained in Example 1 using N-ethyl-N’ 
(3-dimethylaminopropyl) carbodiimide (EDC) hydro 
chloride as a coupling agent. Adopting the procedure 
analogous to that described in Example 2, 115 mg of the 
PC bound to the PVP type copolymer is obtained. The 
content of PC inhibitory moieties in the resulting 
polymer-inhibitor is determined to be 4.8 mole % from 
all monomer units of the copolymer. 
EXAMPLE 12 
1.62 g of dextran (MW 70,000; Pharrnacia Uppsala, 
Sweden) is dissolved in 40 ml of 0.1 mol l—1 borate 
buffer pH 8.00, 1.08 g of 1,2-epoxy-3-bromopropane is 
added and the mixture is vigorously stirred at 30° C. for 
4 hours. The reaction mixture is then extracted with 
ethylacetate, the aqueous layer is separated, 20 ml of 
concentrated ammonium hydroxide is added to it and 
the solution is stirred at ambient temperature for 24 
hours. The solution is then neutralized, dialysed against 
distilled water and the resulting dextran derivative 
(Dextran-NI-h) is ?nally puri?ed by GPC on a Sepha 
dex G-25 column. 
Yield 0.84 g. Analysis shows 6.2 mole % of NH; 
groups per mole of anhydroglucose units. 
58.6 mg (0.1 nmol) of peptidyl-carbamate hemisucci 
nate inhibitor (compound 5 of Scheme 1) prepared ac 
cording to Example 1 is reacted with 21 mg of EDC 
(0.11 mmol) in 1.0 ml of DMF at 0° C. After 60 minutes 
a solution of 260 mg of the above Dextran-HN; in 2 ml 
of 0.1 mol l-1 borate buffer pH 9.00 is added and the 
mixture is stirred in an ice bath for another 16 hours. 
The reaction mixture is then diluted with 3 ml of 0.3 mol 
1-1 NaCl and applied onto a Sephadex G-25 column. 
The dextran-bound PC inhibitor is isolated from the 
collected high-molecular-weight fraction by freeze-dry 
mg. 
Yield: 210 mg, 3.2 mole % of PC inhibitory units per 
mole of anlydroglucose units. The inhibition of the 
elastase activity by the polymer-bound inhibitors pre 
pared in accordance with the invention is evaluated 
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according to the procedure described in detail hereinbe 
low. 
EXAMPLE l3 
Enzyme Activity Inhibition Test 
All enzyme assays are performed spectrophotometri 
cally at 25 C using CARY 219 or 2200 Varian Spec 
trometers. The activity of PPE is measured using 5 
Boc-L-alinine p-nitrophenyl ester (Boc-Ala-ONP), as 
the substrate and monitoring the absorbance at 347.5 nm 
(p-nitrophenol). The activity of HLE is measured using 
methoxy succinyl-L-analyl-L-alanyl L-prolyl-L-valine 
p-nitroanilide (MeO-Suc-Ala-Ala-Pro-Val-NA), as the 
substrate and following the absorbance at 410 nm (p 
nitroaniline). Active inhibitors are tested against other 
serine dependent proteolytic enzymes such as trypsin 
and chymotrypsin using their respective substrates, 
N-benzoyl-L-arginine ethyl ester, N-benzoyl-L-tyrosine 
ethyl ester and monitoring the absorbance at 253 and 
256 respectively. 
Screening Test (Time Course) Assays for PPE and 
HLE 
Buffer: 
for PPE 0.05 M sodium dihydrogen phosphate buffer, 
pH 6.5, 
for HLE 0.1M HEPES (N-2 hydroxy ethyl pipera 
zine-N-Z-ethanesulfonic acid) buffer pH 7.4 con 
taining 0.5M sodium chloride and 10% dimethyl 
sulfoxide. 
Substrate: 
for PPE, t-Boc-Ala-ONP (1.0x 10-2M in methanol), 
for HLE, MeO Suc-Ala-Ala-Pro-Val-NA 
(1.0x l0*2M in dimethyl sulfoxide). 1 
Inhibitor: 2.0X10-3M in dimethyl sulfoxide 
Enzyme: 
for PPE: 1.5 mg in 5 ml of 0.05M sodium phosphate 
buffer, pH 6.5. 
for HLE: 1 mg in 2.4 ml of 0.05M sodium acetate 
buffer, pH 5.5. 
Procedure: 
0.1 ml of the inhibitor and 0.1 ml of the substrate are 
added to 2.7 ml of sodium phosphate buffer in two 
quartz cuvettes The cuvettes are thermally equili 
brated in the spectrophotometer for two minutes 
and the absorbance balanced at 347.5 nm. 
PPE (0.1 ml in buffer) is added to the sample cuvette, 
and 0.1 ml buffer is added to the reference cuvette. 
The mixture is shaken for twenty seconds and the 
increase in absorbance monitored for thirty min 
utes. 
Control Experiment 0.1 ml dimethyl sulfoxide are 
added to both cuvettes instead of inhibitor solution. 
Methods of Enzymatic Assay 
EXAMPLE l4 
Steady State Kinetics for Determination of Kj of 
Polymer-Bound PC Inhibitor and Free PC Inhibitor 
Reagents: 
Buffer: 0.1M HEPES (N-2 hydroxy ethyl piperazine 
N-Z-ethanesulfonic acid) buffer pH 7.5 containing 
0.05M NaCl and 10% dimethyl sulfoxide. 
Substrate: MeO-Suc-Ala-Ala-Pro-Val-NA, 
8.47, 4.23)>< 104M in dimethyl sulfoxide. 
Enzyme: for HLE: 0.27 mg in 4.2 ml of 0.05M sodium 
acetate buffer, pH 5.5. 
(1.27, 
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Inhibitor: Polymer-bound inhibitor (2.09, 1.05, 0.42, 
0.2l)>< lO-5M in 0.05M potassium dihydrogen phos 
phate buffer, pH 6.5. 
Free inhibitor (6.98, 3.49, 1.74, 0.70)>< 1O"3M in di 
methyl sulfoxide. 
Procedure: 33 ul of substrate, 33 ul of inhibitor and 33 
ul of dimethylsulfoxide (or 33 ul of HEPES buffer for 
the free PC inhibitor experiments) are added to 1.9 ml of 
HEPES buffer in each of two quartz cuvettes. The 
curvettes are thermally equilibrated in the spectropho 
tometer at 25 C for two minutes, and the absorbance is 
balanced at 410 nm. 
The enzyme (33 ul) is added to the sample cuvette 
and 0.05M sodium acetate buffer (33 ul) added to the 
reference cuvette. After shaking the mixture for ?fteen 
seconds, the increase in absorbance is monitored for 
three minutes at 410 nm. 
Controls: 
Controls are run by adding 33 ul of 0.05M potassium 
dihydrogen phosphate buffer pH 6.5 in place of polym 
er-bound PC inhibitor (04 33 uL of dimethylsulfoxide in 
place of free PC inhibitor). 
The Ki values are determined from Dixon plots and 
slope replots of Lineweaver-Burke plots. The Ki for 
polymer bound free PC inhibitor is 8.0 X lO-7M and the 
Ki for the free PC inhibitor is 0.4-1.0X lO—5M. 
EXAMPLE 15 
Preincubation Method (Percent Enzymatic Activity 
Remaining) (for Ki Determination) 
Regents: 
Buffer: 0.1M Hepes buffer pH 7.5 containing 0.05M 
sodium chloride and 10% dimethyl sulfoxide, 
Substrate: MeO-Suc-Ala-Ala-Pro-Val-NA, 
1.26X 10—2M in dimethyl sulfoxide. 
Inhibitor: Polymer bound free PC inhibitor (4.56, 
1.82, 0.91, 0.45)><10-5M in 0.1M Hepes buffer pH 7.5 
containing 0.05M NaCl and 10% dimethyl sulfoxide. 
Enzyme: 2.1 X 104M in 0.05M sodium acetate buffer 
pH 5.5. 
Procedure: 33 ul of the inhibitor and 33 ul of the 
enzyme are added to 1.9 ml of the 0.1M Hepes buffer in 
a quartz cuvette and mixed. The reference cuvette con 
tains 33 uL of the inhibitor, 33 u of 0.05M sodium ace 
tate buffer and 1.90 ml of 0.1M Hepes buffer 
The cuvettes are thermally equilibrated in a spectro 
photometer for 2 minutes and the absorbance balanced 
at 410 nm. At the end of a predetermined incubation 
period (2.5 to 20 minutes), 33 ul of substrate is added to 
both the reference and sample cuvettes and the mixtures 
are shaken for 15 seconds. The reaction is then moni 
tored for 3 minutes and the release of p-niroaniline re 
corded at 410 nm. 
Control: 
Control is conducted as above, except that 33 ul of 
0.1M Hepes buffer is used instead of inhibitor, and is 
considered as 100% activity. 
Ki values are obtained from a reciprocal plot of kobs 
(pseudo ?rst-order rate constant for inhibition) vs. in 
hibitor concentration. 
EXAMPLE 16 
Determination of Presence or Absence of Tight 
Binding for Polymer-bound free PC Inhibitor 
Reagents - 
Buffer: 0.1M Hepes buffer containing 0.05M NaCl 
and 20% dimethyl sulfoxide pH 7.5. 
20' 
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Substrate: MeO-Suc-Ala-Ala-Pro-Val-NA, 
4.23X l0—3M in dimethyl sulfoxide. 
Inhibitor: Polymer bound or free pC inhibitor (5.58, 
2.79, 2.15, 1.86, 1.40, 0.933, 0.698, 0.349, 0.209, 
0.105)>< l0-4M in 0.1M Hepes buffer containing 0.05M 
NaCl and 10% dimethyl sulfoxide pH 7.5. 
Enzyme: 2.25 X l0-6M in 0.5M sodium acetate buffer 
pH 5.5. 
Procedure: 33 ul of the substrate and 33 ul of the 
inhibitor are added to 1.9 ml of the 0.1M Hepes buffer in 
each of two quartz cuvettes, thermally equilibrated for 
2 minutes at 25° C., and absorbance balanced at 410 nm. 
The enzyme (33 ul) is added to the sample cuvette and 
the mixture shaken for 15 seconds The release of p 
nitroaniline is followed at 410 nm for 3 minutes. 0.05M 
sodium acetate buffer (33 ul) is added to the reference 
cuvette in place of the enzyme. 
Control experiment: 
Conducted as above, but 33 ul of the 0.1M Hepes 
buffer is added in place of the inhibitor. 
A velocity versus inhibitor concentration plot is used 
to demonstrate the presence of tight binding between 
polymer bound PC] and the enzyme. 
The data obtained according to the above procedures 
show that the elastase inhibitory capacity (EIC) of the 
free peptidyl carbamate inhibitor is not only retained, 
but improved upon its binding to a water-soluble poly 
mer. 
The dissociation constant of ‘the enzyme-inhibitor 
complex (K,-) can be used as an index of inhibitory po 
tency. When this is done, it is found that upon binding 
the PC inhibitor to the‘ polymer an at least 700 fold 
decrease in the K; value is observed indicating im 
proved potency. FIG. 1 provides comparison of the 
inhibitory activity of the free PC inhibitor (PC-1) 
polymer-bound-PC inhibitor (PHEA-(AE)-PC) (P 
PCl 1) and a natural inhibitor of elastase, i e alpha-l 
proteinase inhibitor (cu-PI). Even if the polymer-bound 
PC inhibitor contains such a low content of PC units as 
1.6 mole % in this case it is at least as active as (ll-PI. 
The polymer PHEA has been shown to lack toxicity 
(Neri, P.; Antoni, G.; Benvenute, F ; Cocola, F. and 
Gazzei, G., J. Med. Chem, 16:893-897 (1973). In fact, it 
is not possible to determine its LD50 in mice and rats 
owing to its extreme tolerability over a period of 40 
days. Daily i.v. injections of PHEA at doses 10 fold 
greater than those likely to be used in man do not induce 
any signi?cant changes in total weight gain or organ 
weight. Moreover, no adverse effect of PHEA on the 
biosynthetic mechanism of the serum proteins or of 
blood cells has been observed (Neri et a1, supra). 
Additionally, PHEA has been shown to lack an 
tigenecity. When pHEA is injected in rabbits and 
guinea pigs according to a wide number of immuniza 
tion patterns no evidence of an immune response to it is 
found. (Neri et a1, supra). 
The invention now being fully described, it will be 
apparent to one of ordinary skill in the art that many 
changes and modi?cations can be made thereto without 
departing from the spirit or scope of the invention as set 
forth herein. 
We claim: 
1. A polymer of the formula 
wherein 
5,162,307 
25 
P is a water soluble polymer comprising at least one 
unit of the formula (AmBn), wherein (AmB,,) is 
substantially non-biodegradable and has an average 
molecular weight of about 1,000 to 500,000 daltons, 
m and n may be the same or different and are about 
5 to 3,000, and A and B may be the same or differ 
ent and at least one of A and B is capable of cova 
lently binding to one of L and R; 
R is a compound selected from the group consisting 
of 
a compound C of the formula 
wherein 
X is oxygen or sulfur; 
R’ is selected from the group consisting of straight 
and secondary branch-chained (C1-C4) alkyl, 
(C2-C3) alkenyl, (C2-C4) alkynyl, (C3-C6) cycloal 
kyl, and benzyl, and 
R2 is selected from the group consisting of substituted 
and unsubstituted phenyl, wherein the substituents 
are selected from the group consisting of nitro, 
penta?uoro, benzyl, CH2CF1CF2CF3, l-lower 
alkyl tetrazolyl, l-phenyltetrazolyl, 2-thioxo-3 
thiazolidinyl-, pyridyl and benzothiazolyl, pro 
vided that when R2 is p-nitrophenyl, R’ is other 
than tert-butyl, benzyl or cyclohexyl, and when X 
is sulfur, R2 is other than benzyl; 
a compound D of the formula: 
R. 
wherein 
X is O or S, 
R2 is selected from the group consisting of phenyl, 
nitrophenyl, ?uorophenyl, —CH2CF2CF1CF3, 
l-lower alkyltetrazolyl, l-phenyltetrazolyl, benzyl, 
Z-thioxo-3-thiazolidinyl, pyridyl and benzothiazo 
lyl, and 
R’ is selected from the group consisting of straight or 
secondary branch chained (C1-C4) alkyl, (C2-C3) 
alkenyl, (C2-C4) alkynyl, (C3-C6) cycloalkyl, and 
benzyl, provided that when R2 is p-nitrophenyl R’ 
is other than tertiary-butyl, benzyl or cyclohexyl, 
and when X is sulfur, R2 is other than benzyl; and 
a compound E of the formula 
II 
Z-Pro-Cl-h-N-C-O F 
CH(CH3)2 
wherein 
Z is -O-Suc-Ala-Ala; 
each said R being covalently bound to L or to one of 
A and B, 
15 
25 
35 
45 
50 
55 
65 
26 
L is selected from the group consisting of a covalent 
bond and a linker group which is covalently bound 
to R and one of A and B; and 
q is about 1 to m+n, the resulting polymer p contain 
ing at least multiple units of R. 
2. The polymer of claim 1, wherein 
A is a compound of the formula 
CO 
I 
R 
wherein m=o or 1 and n=b 1 or 0 respectively and 
R is selected from the group consisting of OH, 
2-hydroxyethyl amine, 2-hydroxypropylamine, 
3-hydroxypropyl amine, 2,3-dihydroxypropyl 
amine, 2-hydroxybutylamine and 4-hydroxybutyla 
mine; and 
B is a compound of the formula (1) above, wherein R 
is selected from the group consisting of NH2, 
NH-—-NH2, ——NH--R’—NHZ wherein R’ is 
(CZ-C10) alkyl or (C6-C3) aryl, and NH—R"--OH 
wherein R’ is (C2-C3) alkyl or aryl. 
3. The polymer of claim 1, wherein 
the polymer P is poly-a1B-(N(2-hydroxyethyl)-D,L 
asparagine). 
4. The polymer of claim 1 wherein 
A is selected from the group consisting of N-2-vinyl 
pyrrolidone, N-hydroxypropylmethacrylamide, 
2-hydroxyethyl methacrylate and acrylamide, 
B is selected from the group consisting of amino 
(C2—C6) alkylmethacrylamide, amino (Cr-C5) al 
kylacrylamide, amino (C2-C6) alkyl maleic acid 
monoamide, O-alkyl acrylate and methacrylate 
where alkyl is of the general formula CHz-CH 
(OH)—CH2—NH—R'—NH2 where R’ is C2-C6 
hydrocarbon. 
5. The polymer of claim 1, wherein 
the polymer P is a copolymer of poly (N-2-vinylpyr 
rolidone). 
6. The polymer of claim 1, wherein 
the polymer P is a polysaccharide selected from the 
group consisting of dextran, carboxymethyl cellu 
lose, alginic acid and hyaluronic acid. 
7. The polymer of claim 1, wherein 
A and B are one and the same. 
8. The polymer of claim 1, wherein 
L is of the formula —-NH--R-—NH—, wherein R is 
selected from the group consisting of a covalent 
bond, (C1-C6) alkyl, (C3-C6) hydroxyalkyl and 
(C6-C8) aryl, or wherein 2 to 4 of the alkyl groups 
are linked together by heteroatoms selected from 
the group consisting of N,O and S or by —N 
H—CO-. 
9. The polymer of claim 1, wherein 
L is a covalent bond. 
10. The polymer of claim 1, wherein 
R is compound C; 
R’ is —CH(CH3)2; and 
R2 is l-methyltetrazol. 
11. The polymer of claim 1, wherein 
R is compound C; and 
R’ is selected from the group consisting of 
-—CI-I(CH3)2, —CH2CH2CH3, —CH3, -C(CH3)3, 
cycopropyl, cyclohexyl and benzyl. 

